Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response evaluation of ALK tree AIT for birch pollen allergic rhinoconjunctivitis
2012-000031-59Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- May 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ambrosia artemisiifolia allergen extract in birch pollen allergy and allergic rhinoconjunctivitis (ARC) (6 arms), sponsored by ALK-Abelló. Primary endpoint: Average rhinoconjunctivitis daily symptom score during the birch pollen season. Started May 2012; status: completed.
02
Drugs
ambrosia artemisiifolia allergen extract
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2012-000031-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000031-59.